I asked Elon Musk Ai’s
opinion, is partnership Roche & Herantis Pharma potentiial and viable.
Answer:
First to Stop (or Cure) PD? Not Quite—But Game-Changers in the Works
PD’s brutal—no cure, just symptom managers. “Stopping” progression is the holy grail for disease-modifiers, and both programs hype that potential, but neither’s there yet:
• HER-096: Fresh off Phase 1b success (safe, brain-penetrant, stable symptoms), plus a clean 6-month tox study in Nov 2025. It’s positioned as a potential “first-in-class” to halt progression by hitting root causes, with full biomarkers due end-2025. Phase 2 efficacy readouts? Not till 2027-ish. Backed by MJFF and Parkinson’s UK, it’s promising but early.
• Roche’s Prasinezumab: Further along in Phase III (starting late 2025/early 2026), with data showing motor slowdown in subsets. If it pans out, it could be the first approved modifier to slow PD—not cure, but a massive leap. Roche’s betting big, calling it a “revolution” in neurodegeneration.
Neither’s a cure (reversing damage fully? Decades away, if ever). But prasinezumab might claim “first to slow” bragging rights sooner, while HER-096 could differentiate on repair. If they partnered, it’d be a powerhouse combo—synergistic mechanisms, shared trials?